Mobile App Receives FDA Clearance for Diagnostic Image Viewing on Smart Phones, Tablets
By MedImaging International staff writers Posted on 04 Oct 2011 |
A new medical app (application) ensures the security of confidential patient diagnostic images and information.
Calgary Scientific, Inc. (Calgary, Alberta, Canada) has received clearance from the United States (US) Food and Drug Administration (FDA) to market its medical imaging application, ResolutionMD Mobile, as a mobile diagnostic application, in the United States. With this secure, highly scalable, server-based software solution, physicians located anywhere can rapidly access, view, and interact with patient images and reports stored within any healthcare facility, and render a clinical diagnosis using their mobile devices. Prior nondiagnostic versions of this product are currently distributed and licensed under original equipment manufacturer (OEM) agreements with global leaders in medical imaging and information technology. In addition to the recent FDA clearance, ResolutionMD Mobile has also been licensed by Health Canada and it bears the CE marking for distribution in Europe.
The ResolutionMD mobile product was purpose-built from the existing ResolutionMD software, which first received FDA clearance in 2006. ResolutionMD Mobile utilized the power of Calgary Scientific’s PureWeb platform technology, which allows ResolutionMD to support simultaneously multiple mobile devices and operating systems. This initial FDA clearance applies to versions of the solution running on Apple (Cupertino, CA, USA) iPhone and iPad devices.
The mobile app offers excellent performance, advanced capabilities, and complete security, utilizes minimal bandwidth and offers strong performance even on 3/4G wireless, and ensures that no highly sensitive or confidential patient information is ever retained on the mobile device. The patient image data cannot be lost or stolen, as in the case of conventional mobile-device rendered software, which requires that data to be sent to the mobile device. The flexible, highly scalable, and easily installed environment of ResolutionMD Mobile expands the delivery of Calgary Scientific's image rendering technologies to empower healthcare organizations, physicians, and patients to view images and reports, provide considerably enhanced levels of patient care, and reduce healthcare system costs.
“We worked very closely with the FDA to identify and address the challenge of delivering the advanced visualization and integrated PACS [picture archiving and communication system] functionality of our ResolutionMD server to various mobile devices,” said Kyle Peterson, director of regulatory and corporate affairs of Calgary Scientific. “Extensive bench testing results and reads performed by practicing radiologists using typical but highly challenging cases for CT [computed tomography] and MR [magnetic resonance] were amongst the wide variety of supportive materials and studies submitted to the FDA during the course of this extensive process, which validated the primary diagnostic use of ResolutionMD Mobile.”
“The ability to view diagnostic quality images on mobile devices promises to speed healthcare delivery, particularly for urgent conditions or after hours,” stated James A. Brink, MD, professor and chair, department of diagnostic radiology at Yale University School of Medicine (New Haven, CT, USA).
“This is a landmark moment for the Calgary Scientific organization and its family of global and regional OEM and other partners,” said Dr. Byron Osing, chief executive officer and chair, Calgary Scientific. “As the industry clearly understands, lost or stolen patient data is a critical issue in the medical IT [information technology] sector, with regular announcements of significant HIPAA [Health Insurance Portability and Accountability Act] compliance fines being levied and legal settlements in the tens of millions of dollars. The FDA clearance of the ResolutionMD solution is a key strategic step forward for the medical IT sector in enabling a high performance and secure ‘mHealth’ paradigm, as well as ensuring that vast regions of the world that are currently dependent upon wireless connectivity can now leapfrog directly into the realm of advanced Medical solutions, without having to first invest billions of dollars in high speed networks over decades of elapsed time,” stated Dr. Osing.
ResolutionMD Mobile incorporates many advanced capabilities including: Interactive two-dimensional (2D), maximum intensity projection/ multi-planar reformat (MIP/MPR), and 3D sophisticated visualization and anywhere, anytime access to and fully interactive use of MR and CT images. The app also supports Health Insurance Portability and Accountability Act (HIPAA) compliance provides user authentication and encrypted communications further protect confidential patient information. The concurrent support for multiple devices and mobile operating platforms enables ResolutionMD Mobile capabilities on devices such as the Apple iPhone and iPad, as well as Android devices.
Future versions of the server-based software solution will support an expanded list of mobile devices and operating systems, and supplementary applications to the FDA for clinical diagnostic imaging approval on those devices other than the iPhone and iPad will occur in the near future. The ambient light user assessment provides sample images to the user to assess the viewing suitability of current lighting conditions.
Related Links:
Calgary Scientific
Calgary Scientific, Inc. (Calgary, Alberta, Canada) has received clearance from the United States (US) Food and Drug Administration (FDA) to market its medical imaging application, ResolutionMD Mobile, as a mobile diagnostic application, in the United States. With this secure, highly scalable, server-based software solution, physicians located anywhere can rapidly access, view, and interact with patient images and reports stored within any healthcare facility, and render a clinical diagnosis using their mobile devices. Prior nondiagnostic versions of this product are currently distributed and licensed under original equipment manufacturer (OEM) agreements with global leaders in medical imaging and information technology. In addition to the recent FDA clearance, ResolutionMD Mobile has also been licensed by Health Canada and it bears the CE marking for distribution in Europe.
The ResolutionMD mobile product was purpose-built from the existing ResolutionMD software, which first received FDA clearance in 2006. ResolutionMD Mobile utilized the power of Calgary Scientific’s PureWeb platform technology, which allows ResolutionMD to support simultaneously multiple mobile devices and operating systems. This initial FDA clearance applies to versions of the solution running on Apple (Cupertino, CA, USA) iPhone and iPad devices.
The mobile app offers excellent performance, advanced capabilities, and complete security, utilizes minimal bandwidth and offers strong performance even on 3/4G wireless, and ensures that no highly sensitive or confidential patient information is ever retained on the mobile device. The patient image data cannot be lost or stolen, as in the case of conventional mobile-device rendered software, which requires that data to be sent to the mobile device. The flexible, highly scalable, and easily installed environment of ResolutionMD Mobile expands the delivery of Calgary Scientific's image rendering technologies to empower healthcare organizations, physicians, and patients to view images and reports, provide considerably enhanced levels of patient care, and reduce healthcare system costs.
“We worked very closely with the FDA to identify and address the challenge of delivering the advanced visualization and integrated PACS [picture archiving and communication system] functionality of our ResolutionMD server to various mobile devices,” said Kyle Peterson, director of regulatory and corporate affairs of Calgary Scientific. “Extensive bench testing results and reads performed by practicing radiologists using typical but highly challenging cases for CT [computed tomography] and MR [magnetic resonance] were amongst the wide variety of supportive materials and studies submitted to the FDA during the course of this extensive process, which validated the primary diagnostic use of ResolutionMD Mobile.”
“The ability to view diagnostic quality images on mobile devices promises to speed healthcare delivery, particularly for urgent conditions or after hours,” stated James A. Brink, MD, professor and chair, department of diagnostic radiology at Yale University School of Medicine (New Haven, CT, USA).
“This is a landmark moment for the Calgary Scientific organization and its family of global and regional OEM and other partners,” said Dr. Byron Osing, chief executive officer and chair, Calgary Scientific. “As the industry clearly understands, lost or stolen patient data is a critical issue in the medical IT [information technology] sector, with regular announcements of significant HIPAA [Health Insurance Portability and Accountability Act] compliance fines being levied and legal settlements in the tens of millions of dollars. The FDA clearance of the ResolutionMD solution is a key strategic step forward for the medical IT sector in enabling a high performance and secure ‘mHealth’ paradigm, as well as ensuring that vast regions of the world that are currently dependent upon wireless connectivity can now leapfrog directly into the realm of advanced Medical solutions, without having to first invest billions of dollars in high speed networks over decades of elapsed time,” stated Dr. Osing.
ResolutionMD Mobile incorporates many advanced capabilities including: Interactive two-dimensional (2D), maximum intensity projection/ multi-planar reformat (MIP/MPR), and 3D sophisticated visualization and anywhere, anytime access to and fully interactive use of MR and CT images. The app also supports Health Insurance Portability and Accountability Act (HIPAA) compliance provides user authentication and encrypted communications further protect confidential patient information. The concurrent support for multiple devices and mobile operating platforms enables ResolutionMD Mobile capabilities on devices such as the Apple iPhone and iPad, as well as Android devices.
Future versions of the server-based software solution will support an expanded list of mobile devices and operating systems, and supplementary applications to the FDA for clinical diagnostic imaging approval on those devices other than the iPhone and iPad will occur in the near future. The ambient light user assessment provides sample images to the user to assess the viewing suitability of current lighting conditions.
Related Links:
Calgary Scientific
Latest Imaging IT News
- New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
- Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
- AI-Based Mammography Triage Software Helps Dramatically Improve Interpretation Process
- Artificial Intelligence (AI) Program Accurately Predicts Lung Cancer Risk from CT Images
- Image Management Platform Streamlines Treatment Plans
- AI-Based Technology for Ultrasound Image Analysis Receives FDA Approval
- AI Technology for Detecting Breast Cancer Receives CE Mark Approval
- Digital Pathology Software Improves Workflow Efficiency
- Patient-Centric Portal Facilitates Direct Imaging Access
- New Workstation Supports Customer-Driven Imaging Workflow
Channels
Radiography
view channel
World's Largest Class Single Crystal Diamond Radiation Detector Opens New Possibilities for Diagnostic Imaging
Diamonds possess ideal physical properties for radiation detection, such as exceptional thermal and chemical stability along with a quick response time. Made of carbon with an atomic number of six, diamonds... Read more
AI-Powered Imaging Technique Shows Promise in Evaluating Patients for PCI
Percutaneous coronary intervention (PCI), also known as coronary angioplasty, is a minimally invasive procedure where small metal tubes called stents are inserted into partially blocked coronary arteries... Read moreMRI
view channel
AI Tool Tracks Effectiveness of Multiple Sclerosis Treatments Using Brain MRI Scans
Multiple sclerosis (MS) is a condition in which the immune system attacks the brain and spinal cord, leading to impairments in movement, sensation, and cognition. Magnetic Resonance Imaging (MRI) markers... Read more
Ultra-Powerful MRI Scans Enable Life-Changing Surgery in Treatment-Resistant Epileptic Patients
Approximately 360,000 individuals in the UK suffer from focal epilepsy, a condition in which seizures spread from one part of the brain. Around a third of these patients experience persistent seizures... Read more
AI-Powered MRI Technology Improves Parkinson’s Diagnoses
Current research shows that the accuracy of diagnosing Parkinson’s disease typically ranges from 55% to 78% within the first five years of assessment. This is partly due to the similarities shared by Parkinson’s... Read more
Biparametric MRI Combined with AI Enhances Detection of Clinically Significant Prostate Cancer
Artificial intelligence (AI) technologies are transforming the way medical images are analyzed, offering unprecedented capabilities in quantitatively extracting features that go beyond traditional visual... Read moreUltrasound
view channel.jpeg)
AI-Powered Lung Ultrasound Outperforms Human Experts in Tuberculosis Diagnosis
Despite global declines in tuberculosis (TB) rates in previous years, the incidence of TB rose by 4.6% from 2020 to 2023. Early screening and rapid diagnosis are essential elements of the World Health... Read more
AI Identifies Heart Valve Disease from Common Imaging Test
Tricuspid regurgitation is a condition where the heart's tricuspid valve does not close completely during contraction, leading to backward blood flow, which can result in heart failure. A new artificial... Read moreNuclear Medicine
view channel
Novel PET Imaging Approach Offers Never-Before-Seen View of Neuroinflammation
COX-2, an enzyme that plays a key role in brain inflammation, can be significantly upregulated by inflammatory stimuli and neuroexcitation. Researchers suggest that COX-2 density in the brain could serve... Read more
Novel Radiotracer Identifies Biomarker for Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC), which represents 15-20% of all breast cancer cases, is one of the most aggressive subtypes, with a five-year survival rate of about 40%. Due to its significant heterogeneity... Read moreGeneral/Advanced Imaging
view channel
AI-Powered Imaging System Improves Lung Cancer Diagnosis
Given the need to detect lung cancer at earlier stages, there is an increasing need for a definitive diagnostic pathway for patients with suspicious pulmonary nodules. However, obtaining tissue samples... Read more
AI Model Significantly Enhances Low-Dose CT Capabilities
Lung cancer remains one of the most challenging diseases, making early diagnosis vital for effective treatment. Fortunately, advancements in artificial intelligence (AI) are revolutionizing lung cancer... Read moreIndustry News
view channel
GE HealthCare and NVIDIA Collaboration to Reimagine Diagnostic Imaging
GE HealthCare (Chicago, IL, USA) has entered into a collaboration with NVIDIA (Santa Clara, CA, USA), expanding the existing relationship between the two companies to focus on pioneering innovation in... Read more
Patient-Specific 3D-Printed Phantoms Transform CT Imaging
New research has highlighted how anatomically precise, patient-specific 3D-printed phantoms are proving to be scalable, cost-effective, and efficient tools in the development of new CT scan algorithms... Read more
Siemens and Sectra Collaborate on Enhancing Radiology Workflows
Siemens Healthineers (Forchheim, Germany) and Sectra (Linköping, Sweden) have entered into a collaboration aimed at enhancing radiologists' diagnostic capabilities and, in turn, improving patient care... Read more